Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Bistervels (Amsterdam, Netherlands), W. Boersma (Alkmaar, Netherlands), R. Bavalia (Amsterdam, Netherlands), K. Meijer (Groningen, Netherlands), P. Verhamme (Leuven, Belgium), H. Ten Cate (Maastricht, Netherlands), J. Beyer-Westendorf (Dresden, Germany), S. Schellong (Dresden, Germany), B. Hutten (Amsterdam, Netherlands), M. Kovacs (London, Ontario, Canada), M. Cattaneo (Milan, Italy), W. Ghanima (Òslo, Norway), A. Hugman (Sydney, Australia), M. Coppens (Amsterdam, Netherlands), M. Ten Wolde (Almere, Netherlands), D. Stephan (Strasbourg, France), N. Falvo (Dijon, France), D. Brisot (Castelnau Le Lez, France), I. Quere (Montpellier, France), S. Middeldorp (Amsterdam, Netherlands). Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. 3581

Member's Comments

No comment yet.

Related content which might interest you: Rivaroxaban versus standard anticoagulation for the treatment of pulmonary embolism: a real-life study Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 A case-control study on direct oral anticoagulants versus warfarin for acute pulmonary embolism in obese patients Source: Virtual Congress 2021 – Insights into pulmonary embolism Year: 2021 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019 Year: 2020 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019 Year: 2020 Supervised exercise training in patients with chronic thromboembolic pulmonary hypertension (CTEPH) as early follow-up treatment after pulmonary endarterectomy (PEA) – a prospective cohort study Source: Virtual Congress 2020 – Chronic thromboembolic pulmonary hypertension Year: 2020 The controlled study of a 6-month course of acute pulmonary embolism in patients with syncope at admission Source: Eur Respir J 2005; 26: Suppl. 49, 270s Year: 2005 Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis Source: Eur Respir J 2013; 42: 134-144 Year: 2013 Should thrombolysis and sildenafil be given in the acute management of patients with large pulmonary embolism? An assessment of the short and long-term outcomes. Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment Year: 2019 Early discharge of patients with pulmonary embolism: feasibility of domicillary anticoagulation Source: Eur Respir J 2003; 22: Suppl. 45, 219s Year: 2003 Mortality and recurrence during a follow-up of 2 years of pulmonary embolism: Role of anticoagulant therapy Source: Annual Congress 2010 - Pulmonary embolism Year: 2010 Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials Year: 2017 A retrospective cohort study of patients with pulmonary embolism: the impact of comorbidities on patient's outcome Source: Eur Respir J 2016; 48: 555-557 Year: 2016 Safety and efficacy of home-based pulmonary rehabilitation in patients with pulmonary hypertension: Feasibility study of 12 cases Source: Virtual Congress 2020 – Comprehensive care and pulmonary rehabilitation for chronic respiratory diseases Year: 2020 Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Early discharge of patients with pulmonary embolism: a two-phase observational study Source: Eur Respir J 2007; 30: 708-714 Year: 2007 Long-term benefits of pulmonary rehabilitation in COPD patients: 2 year follow-up Source: International Congress 2017 – Novel treatments for rehabilitation of patients with chronic respiratory diseases Year: 2017 One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001 The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019 Long-term outcome with subcutaneous treprostinil sodium in pulmonary hypertension: a 10-year single-centre study Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety. Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019